Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Abbvie Revenues Down 10% in the Quarter | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Abbvie Revenues Down 10% in the Quarter

Humira sales down 25% due to patent loss, while Skyrizi and Rinvoq sales were up 45% and 48% respectively.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Abbvie
1Q Revenues: $12.2 billion (-10%)
1Q Earnings: $241 million (earnings were $4.5 billion in 1Q22)
Comments: Revenues from the Immunology Portfolio were $5.6 billion, down 9%. Global Humira sales were $3.5 billion in the quarter, down 25%. Global Skyrizi sales were $1.4 billion, up 45%. Global Rinvoq sales were $686 million, up 48%. Revenues from the Hematologic Oncology Portfolio were $1.4 billion, down 14%, with Imbruvica revenues of $878 million, down 25%, and Venclexta sales of $538 million, up 14%. Global revenues from the Neuroscience Portfolio were $1.7 billion, up 14%, with Botox Therapeutic revenues up 17% to $719 million and Vraylar revenues up 31% to $561 million. Global revenues from the Aesthetics Portfolio were $1.3 billion, down 5%; Global Botox Cosmetic sales $659 million, up 3%. Global Juvederm sales were down 13% to $355 million. Reported earnings for the three months ended March 31, 2023 included acquired IPR&D and milestones expense of $150 million.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics